Unresectable stage III non-small-cell lung cancer: Have we made any progress?

Table 2 Survival data from phase II and III trials using concurrent chemoradiation therapy followed by consolidation chemotherapy in non-small-cell lung cancer

Trial	Patients (n)	Schedule	Median survival(mo)	Survival (%)
Belani et al[10]	92	Weekly CP + 63 Gy → CP × 2	16.3	17 (3 yr)
Albain et al[96]	50	PE × 2 + 61 Gy → PE × 2	15	15 (5 yr)
Gandara et al[43]	83	PE × 2 + 61 Gy → D × 3	26	29 (5 yr)
Lau et al[97]	34	Weekly C + biweekly P + 61 Gy → CP × 2	17	40 (2 yr)
Hanna et al[44]	73	PE × 2 + 59.4 Gy → D × 3	21.2	27.1 (3 yr)

CP: Carboplatin/paclitaxel; P: Paclitaxel; PE: Cisplatin/etoposide; D: Docetaxel.